EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients Natalia Sutiman, BSc, Shao.

Slides:

Advertisements

Similar presentations

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Advertisements

Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations:

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non–Small Cell Lung Cancers Christos.

SC17.02 Lung Cancer in China: Challenges and Perspectives

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation Alessandro Russo, MD, Tindara.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Swati Kulkarni, MD, Emily T. Vella,

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base Amy C. Moreno,

Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With.

First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status Young Joo Lee, MD, Heung Tae Kim, MD,

Tetsuya Mitsudomi, MD, Hirohito Tada, MD Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Karin J. C. Sanders, MD, Lizza E. Hendriks, MD, Esther G. C

Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

George Blumenschein, MD, John V. Heymach, MD, PhD

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations:

A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary.

EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases Tao.

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

Journal of Thoracic Oncology

Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External.

Geographic Variation in EGFR Mutation Frequency in Lung Adenocarcinoma May Be Explained by Interethnic Genetic Variation Lars Soraas, MSc, Justin Stebbing,

Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non–Small-Cell Lung Cancer with Activating EGFR Mutation Bhumsuk.

First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally.

The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma Benjamin Izar, MD, PhD,

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non–Small Cell Lung.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

ED11.01 Systemic Therapy for Advanced Oncogene-Driven NSCLC

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer Philip C. Mack,

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta- analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in.

A Randomized Phase II Trial of Single-Agent Gemcitabine, Vinorelbine, or Docetaxel in Patients with Advanced Non-small Cell Lung Cancer Who Have Poor.

Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non- small Cell Lung Cancer: Systematic Review and Indirect Comparison Meta-Analysis.

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung.

Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study Alex Chang, MD,

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Clinical Relevance of Our Multimodality Prognostic Score

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective.

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Combined Small Cell Carcinoma of the Lung: Is It a Single Entity?

International Thymic Malignancies Interest Group: A Way Forward

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Giorgio V.

Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer Elena Bolzacchini, MD,

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Two Rare Exon 21 EGFR Mutations in Patients Treated with Gefitinib

Presentation transcript:

EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients Natalia Sutiman, BSc, Shao Weng Tan, M.B.B.S., Eng Huat Tan, M.B.B.S., Wan Teck Lim, M.B.B.S., Ravindran Kanesvaran, M.B.B.S., Quan Sing Ng, M.B.B.S., Amit Jain, M.B.B.S., Mei Kim Ang, M.B.B.S., Wan Ling Tan, M.B.B.S., Chee Keong Toh, M.B.B.S., Balram Chowbay, PhD Journal of Thoracic Oncology Volume 12, Issue 3, Pages 529-538 (March 2017) DOI: 10.1016/j.jtho.2016.11.2225 Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Comparison of progression-free survival (PFS) curves of patients with advanced NSCLC treated with first-line gefitinib therapy between different EGFR mutation types (A), exon 19 deletions versus L858R (B), different exon 19 mutation subtypes (C), different starting codons of exon 19 deletions (D), and different exon 21 mutation subtypes (E). cum, cumulative; ELREA, (delE746_A750). Journal of Thoracic Oncology 2017 12, 529-538DOI: (10.1016/j.jtho.2016.11.2225) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Comparison of overall survival curves of patients with advanced NSCLC treated with first-line gefitinib therapy between different EGFR mutation types (A), exon 19 deletions versus L858R (B), different exon 19 mutation subtypes (C), different starting codons of exon 19 deletions (D), and different exon 21 mutation subtypes (E). cum, cumulative; ELREA, (delE746_A750). Journal of Thoracic Oncology 2017 12, 529-538DOI: (10.1016/j.jtho.2016.11.2225) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 1A Journal of Thoracic Oncology 2017 12, 529-538DOI: (10.1016/j.jtho.2016.11.2225) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 1B Journal of Thoracic Oncology 2017 12, 529-538DOI: (10.1016/j.jtho.2016.11.2225) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 1C Journal of Thoracic Oncology 2017 12, 529-538DOI: (10.1016/j.jtho.2016.11.2225) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 1D Journal of Thoracic Oncology 2017 12, 529-538DOI: (10.1016/j.jtho.2016.11.2225) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 1E Journal of Thoracic Oncology 2017 12, 529-538DOI: (10.1016/j.jtho.2016.11.2225) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 2A Journal of Thoracic Oncology 2017 12, 529-538DOI: (10.1016/j.jtho.2016.11.2225) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 2B Journal of Thoracic Oncology 2017 12, 529-538DOI: (10.1016/j.jtho.2016.11.2225) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 2C Journal of Thoracic Oncology 2017 12, 529-538DOI: (10.1016/j.jtho.2016.11.2225) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 2D Journal of Thoracic Oncology 2017 12, 529-538DOI: (10.1016/j.jtho.2016.11.2225) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 2E Journal of Thoracic Oncology 2017 12, 529-538DOI: (10.1016/j.jtho.2016.11.2225) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions